Original research articles published in Nature Medicine range from basic findings that have clear implications for disease pathogenesis and therapy to the earliest phases of human investigation. Aiming to keep Ph.D. and M.D. readers informed of a wide range of biomedical research findings, the journal publishes the latest advances in cancer biology, vascular biology, neuroscience, inflammatory disease, infectious disease and metabolic disorders, among other fields. Reviews, Perspectives and other commissioned content clarify and give context to these biomedical research advances, and the News section reports on the latest developments in drug research and development. http://feeds.nature.com/nm/rss/current Nature Publishing Group en © 2026 Macmillan Publishers Limited, part of Springer Nature. All rights reserved. Nature Medicine © 2026 Macmillan Publishers Limited, part of Springer Nature. All rights reserved. permissions@nature.com https://www.nature.com/uploads/product/nm/rss.gif http://feeds.nature.com/nm/rss/current https://www.nature.com/articles/s41591-026-04421-7 Nature Medicine, Published online: 12 June 2026; doi:10.1038/s41591-026-04421-7

The Hong Kong Genome Project established a genome sequencing database that provides improved diagnoses for patients and more efficient, population-tailored carrier status screening. Actionable pharmacogenomic variants were identified in almost all participants, informing drug prescriptions. This work establishes a genomic resource and a transferable model for equitable precision medicine in underrepresented populations worldwide.]]> doi:10.1038/s41591-026-04421-7 Nature Medicine, Published online: 2026-06-12; | doi:10.1038/s41591-026-04421-7 2026-06-12 Nature Medicine 10.1038/s41591-026-04421-7 https://www.nature.com/articles/s41591-026-04421-7 https://www.nature.com/articles/s41591-026-04465-9 Nature Medicine, Published online: 12 June 2026; doi:10.1038/s41591-026-04465-9

Pramipexole, in patients with major depressive disorder, dysthymia or bipolar depression, reduced Snaith−Hamilton Pleasure Scale scores significantly compared to placebo.]]> Filip VentorpMarie AspSofia OlssonJesper LindahlStefan MöllerMartina SvenssonFilip ÄngebyArmida PravdinskeJohanna TjernbergSusann SchreyDarya StåhlViktor MagnussonEmilia EliassonAnna Agelii-WeberErika StålhammarDanielle van WestenTomas DeierborgKristoffer N. T. MånssonDiego A. PizzagalliÅsa HammarÅsa B. TornbergJohannes BjörkstrandDaniel Lindqvist doi:10.1038/s41591-026-04465-9 Nature Medicine, Published online: 2026-06-12; | doi:10.1038/s41591-026-04465-9 2026-06-12 Nature Medicine 10.1038/s41591-026-04465-9 https://www.nature.com/articles/s41591-026-04465-9 https://www.nature.com/articles/s41591-026-04431-5 Nature Medicine, Published online: 12 June 2026; doi:10.1038/s41591-026-04431-5

In an independent evaluation, frontier large language models outperformed specialized clinical artificial intelligence tools on medical knowledge, clinician alignment and real-world clinical queries.]]> Krithik VishwanathAnton AlyakinMrigayu GhoshAli HageSean N. NeifertCordelia OrillacNataniel J. MandelbergHammad A. KhanJin Vivian LeeJie J. YaoWilliam Robert SmallAakaash VarmaD. Brock HewittYindalon AphinyanaphongsDaniel Alexander AlberEric Karl Oermann doi:10.1038/s41591-026-04431-5 Nature Medicine, Published online: 2026-06-12; | doi:10.1038/s41591-026-04431-5 2026-06-12 Nature Medicine 10.1038/s41591-026-04431-5 https://www.nature.com/articles/s41591-026-04431-5 https://www.nature.com/articles/s41591-026-04409-3 Nature Medicine, Published online: 11 June 2026; doi:10.1038/s41591-026-04409-3

We analyzed brains from octogenarians and cognitively resilient centenarians to understand why some individuals with substantial Alzheimer’s disease pathology develop dementia whereas others remain cognitively intact. Spatial transcriptomics revealed gene expression changes in discrete tissue domains surrounding amyloid plaques and tau pathology that distinguish early, clinically silent, disease from later stages associated with cognitive decline.]]> doi:10.1038/s41591-026-04409-3 Nature Medicine, Published online: 2026-06-11; | doi:10.1038/s41591-026-04409-3 2026-06-11 Nature Medicine 10.1038/s41591-026-04409-3 https://www.nature.com/articles/s41591-026-04409-3 https://www.nature.com/articles/s41591-026-04510-7 Nature Medicine, Published online: 11 June 2026; doi:10.1038/s41591-026-04510-7

Clinical Profile and Genomic Characterization of the 2026 Bundibugyo Virus Index Case in Uganda]]> Andrew NsawotebbaIsaac SsewanyanaAlisen AyitewalaMisaki WayengeraStephen KanyereziJonathan KabazziValeria NakintuAloysious SsemagandaRodney KisuuleSteven SsekyondwaHellen Rosette OundoRonald KasujjaAmable AyebareStephen BalinandiGodfrey PimunduTonny MuyigiGodrine Mayanja ByekwasoIbrahim MugerwaFrancis KakoozaSusan NamboozoAidah NamakulaJudith KyokushabaMoses JolobaWinters MutambaMudarshiru BbuyeBruce KirengaPontiano KaleebuWilber SabiitiReginald Rony BahatungireCaroline AcholaSulaiman IkobaAllan MurutaBernard LubwamaAtek KagiritaHenry Kyobe BosaJane Ruth AcengSusan NabaddaCharles OlaroDiana Atwine doi:10.1038/s41591-026-04510-7 Nature Medicine, Published online: 2026-06-11; | doi:10.1038/s41591-026-04510-7 2026-06-11 Nature Medicine 10.1038/s41591-026-04510-7 https://www.nature.com/articles/s41591-026-04510-7 https://www.nature.com/articles/s41591-026-04444-0 Nature Medicine, Published online: 10 June 2026; doi:10.1038/s41591-026-04444-0

Announced in this Comment and in collaboration with Nature Medicine is the convening of the Brain Health for Economic Resilience Commission, a global, transdisciplinary effort to define, measure and operationalize brain health and cognitive capacity as foundational drivers of economic resilience.]]> Harris A. EyreRym AyadiAgustín IbáñezMie RizigSimon Fischer-Baum doi:10.1038/s41591-026-04444-0 Nature Medicine, Published online: 2026-06-10; | doi:10.1038/s41591-026-04444-0 2026-06-10 Nature Medicine 10.1038/s41591-026-04444-0 https://www.nature.com/articles/s41591-026-04444-0 https://www.nature.com/articles/s41591-026-04436-0 Nature Medicine, Published online: 10 June 2026; doi:10.1038/s41591-026-04436-0

Phase 1 results reveal that BBM-P002, a dual-target gene therapy co-delivering TH and DDC, is safe and well tolerated in Parkinson’s disease, with 12-month motor improvements signaling therapeutic potential.]]> Mengyue NiuJifeng GuoYuchao YangQian XuCheng ChengHao LiNingdi LuoHaiyan ZhouPingchen ZhangYuanyuan LiNingyuan WangChunyi WangDianyou LiZhengyu LinPeng HuangZhiquan YangZhuanyi YangYanyan SongJing ZhengWei JiangZengmin DuYuanxin QiHuirong PengYuyan TanXintian HuXiao XiaoLu ShenJiaji LinJun Liu doi:10.1038/s41591-026-04436-0 Nature Medicine, Published online: 2026-06-10; | doi:10.1038/s41591-026-04436-0 2026-06-10 Nature Medicine 10.1038/s41591-026-04436-0 https://www.nature.com/articles/s41591-026-04436-0 https://www.nature.com/articles/s41591-026-04482-8 Nature Medicine, Published online: 09 June 2026; doi:10.1038/s41591-026-04482-8

Bundibugyo Ebola without vaccines or therapeutics: why public health fundamentals matter more than border closures]]> Ngashi NgongoMosoka Papa FallahNebiyu DerejeYap BoumJean Kaseya doi:10.1038/s41591-026-04482-8 Nature Medicine, Published online: 2026-06-09; | doi:10.1038/s41591-026-04482-8 2026-06-09 Nature Medicine 10.1038/s41591-026-04482-8 https://www.nature.com/articles/s41591-026-04482-8